Summarized by Masters of Longevity from Longevity Technology.
Analysis of why Chinese biotechs currently move clinical programs much faster than Western peers, where that speed yields deals, and what barriers remain for global adoption.
Key Takeaways
- Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
- Speed is the one thing in drug development that money cannot easily buy.
- Chinese biopharma companies, according to our Longevity Biotech Report , can move a drug through clinical trials 50–70% faster than their US counterparts – a head start now visible in the deal data, and one Washington has certainly noticed.
